Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $219
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $216 to $219.
August 02, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $216 to $219.
The Outperform rating and increased price target from a reputable analyst at Oppenheimer is likely to boost investor confidence in Neurocrine Biosciences, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100